Predicting malnutrition after surgery in women with early cervical cancer
Tests a CT scan tool to predict malnutrition in women after cervical cancer surgery.
Plain-language title generated from the registry record
Registry title: Radiomics-based Malnutrition for Cervical Cancer.
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 80 with stage IB1-IIA2 cervical cancer. They had radical surgery and then radiotherapy or chemoradiotherapy.
- Age
- 18 to 80 years
- Sex
- Women only
- Disease stage
- Cervical cancer, stage IB1-IIA2 (FIGO 2014), confirmed after pelvic lymph node removal and radical hysterectomy
- Earlier treatment
- Must have had pelvic lymphadenectomy and radical hysterectomy, with no treatment before the surgery. Must get radiotherapy or chemoradiotherapy within one week after admission at the ZJPPH.
Main reasons for not taking part
- Poor image quality or visible artifacts around the L3 psoas
- Chemotherapy or radiation before the surgery
- Poor bone marrow, liver or kidney function that makes treatment hard to tolerate
- Taking part in another clinical trial
- Pregnancy, breast feeding, or not using birth control
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05709769, who can take part
Where in China
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhejiang Provincial People's Hospital
- Trial code
- NCT05709769
- Record updated
- 20 July 2023
- Original description
Loss of skeletal muscle, is one of the most prevalent symptoms of malnutrition, and has been frequently reported as a negative factor in cancer patients at any disease stage. In this study, we are planning to firstly analyze the radiomics features of psoas extracted at the level of the third lumbar vertebra (L3) and then, develop a CT-based radiomics nomogram prediction model for predicting malnutrition based on their Patient-Generated Subjective Global Assessment (PG-SGA) scores in patients with International Federation of Gynecology and Obstetrics (FIGO, 2014 version) stage IB1-IIA2 cervical cancer (CC) who received postoperative radiotherapy/chemoradiotherapy (RT/CRT).Read full original descriptionShow less
Development and Validation of a CT-Based Radiomics Nomogram for the Prediction of Postoperative Malnutrition in Stage IB1-IIA2 Cervical Cancer (Nutrition Helper-1).
Loss of skeletal muscle, is one of the most prevalent symptoms of malnutrition, and has been frequently reported as a negative factor in cancer patients at any disease stage. In this study, we are planning to firstly analyze the radiomics features of psoas extracted at the level of the third lumbar vertebra (L3) and then, develop a CT-based radiomics nomogram prediction model for predicting malnutrition based on their Patient-Generated Subjective Global Assessment (PG-SGA) scores in patients with International Federation of Gynecology and Obstetrics (FIGO, 2014 version) stage IB1-IIA2 cervical cancer (CC) who received postoperative radiotherapy/chemoradiotherapy (RT/CRT).
Inclusion: Patients received pelvic lymphadenectomy and radical hysterectomy, and pathological diagnosis of CC; Patients had stage IB1-IIA2 CC based on the 2014 FIGO staging system for cervical cancer; Patients received postoperative RT/CRT within one week after admission at the ZJPPH; Patients must have Eastern Cooperative Oncology Group performance status 0-2; No treatments prior to radical surgery; Normal marrow function and the blood tests must be collected within 7 days from enrollment with a hemoglobin of ≥ 80g/L (can be transfused with red blood cells pre-study), an white blood cell (WBC) counts of ≥ 3.0×109/L，a neutrophil count of ≥ 2.0×109/L, , a platelet count of ≥100×109/L, a total bilirubin (TBil) of ≤ 1.0 upper normal limitation (UNL), a creatinine (Cr) of ≤ 1.0 UNL, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤ 2.5 UNL, Alkaline phosphatase (AKP) ≤5.0 UNL. and no major electrocardiogram abnormalities; Patient does not have a known allergy to platinum (cisplatin or carboplatin) or compounds of similar biologic composition; Patients must be with good compliance and agree to accept nutritional therapy; Informed consent signed. -.
Exclusion: Prior treatments of chemotherapy or irradiation; Poor bone marrow, liver and kidney functions, which would make chemotherapy or radiotherapy intolerable; Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities; The subject has had another active malignancy within the past five years; Poor image quality or visible artifacts around the L3 psoas; Participating in other clinical trials; Pregnancy, breast feeding, or not adopting birth control; Poor image quality or visible artifacts around the L3 psoas. -.